Pure Global

Safety and Tolerability of RPESC-derived RPE Transplantation in Patients With Dry Age-related Macular Degeneration (AMD) - Trial NCT04627428

Access comprehensive clinical trial information for NCT04627428 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Luxa Biotechnology, LLC and is currently Not yet recruiting. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 18 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT04627428
Phase 1/2
Not yet recruiting
biological
Trial Details
ClinicalTrials.gov • NCT04627428
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Safety and Tolerability of RPESC-derived RPE Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
A Phase1/2a, Open-Label Study to Evaluate the Safety and Tolerability of RPESC-derived RPE Transplantation as Therapy for Dry Age-related Macular Degeneration (AMD)

Study Focus

RPESC-RPE-4W

Interventional

biological

Sponsor & Location

Luxa Biotechnology, LLC

Ann Arbor, United States of America

Timeline & Enrollment

Phase 1/2

Feb 01, 2022

Sep 01, 2025

18 participants

Primary Outcome

Safety and tolerability of RPESC-RPE-4W transplantation

Summary

The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W
 as therapy for dry AMD.

ICD-10 Classifications

Peripheral retinal degeneration
Corneal degeneration
Hereditary retinal dystrophy
Optic atrophy in diseases classified elsewhere
Disorders of choroid and retina

Data Source

ClinicalTrials.gov

NCT04627428

Non-Device Trial